| US 7,566,542 B2 | ||
| Use of protein ASC as a marker for breast cancer | ||
| Gabriele Pestlin, München (Germany); Herbert Andres, Penzberg (Germany); Peter Berndt, Basel (Switzerland); Marie-Luise Hagmann, Penzberg (Germany); Johann Karl, Peissenberg (Germany); Hanno Langen, Steinen (Germany); and Werner Zolg, Weilheim (Germany) | ||
| Assigned to Roche Diagnostics Operations, Inc., Indianapolis, Ind. (US) | ||
| Filed on Apr. 14, 2006, as Appl. No. 11/404,218. | ||
| Application 11/404218 is a continuation of application No. PCT/EP2004/011597, filed on Oct. 15, 2004. | ||
| Claims priority of application No. 03023507 (EP), filed on Oct. 15, 2003. | ||
| Prior Publication US 2006/0257952 A1, Nov. 16, 2006 | ||
| Int. Cl. G01N 33/53 (2006.01); G01N 33/574 (2006.01); G01N 33/48 (2006.01); G01N 33/536 (2006.01); G01N 33/537 (2006.01); G01N 33/577 (2006.01) | ||
| U.S. Cl. 435—7.1 [435/7.23; 435/7.9; 435/7.91; 435/7.92; 435/7.93; 435/7.94; 435/7.95; 436/501; 436/518; 436/536; 436/64] | 7 Claims |
| 1. A method for a diagnosis of breast cancer comprising the steps of:
(a) providing a liquid sample obtained from an individual,
(b) directly contacting the sample with an antibody specific for human apoptosis-associated speck-like protein containing
a caspase-associated recruitment domain (ASC) under conditions whereby a complex is formed between the antibody and ASC and
wherein the antibody has an affinity of at least 107 l/mol for ASC,
(c) measuring an amount of complex formed, and
(d) comparing the amount of complex formed to a control amount determinative of the diagnosis of breast cancer, wherein the
liquid sample is selected from the group consisting of serum, plasma, whole blood, and nipple aspirate fluid, and further
wherein “directly” excludes contacting cellular and tissue samples separated from the liquid sample obtained in step (a).
|